Evidence map›Paper›PMID 35967342›Full record

ArticleFrontiers in immunology2022

Proposed clinical phases for the improvement of personalized treatment of checkpoint inhibitor-related pneumonitis.

Chengzhi Zhou, Yilin Yang, Xinqing Lin, Nianxin Fang, Likun Chen, Juhong Jiang, Haiyi Deng, Yu Deng, Minghui Wan, Guihuan Qiu and 22 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Pulmonary toxicity of immune checkpoint immunotherapy.The Journal of clinical investigation · 2024
    Review
  10. Review
  11. Article
  12. Observational
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors at 18 institutions in 4 countries.

Chengzhi ZhouState Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, First Affiliated Hospital, Guangzhou Institute of Respiratory Health, Guangzhou Medical University, Guangzhou, China.
Yilin YangState Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, First Affiliated Hospital, Guangzhou Institute of Respiratory Health, Guangzhou Medical University, Guangzhou, China.
Xinqing LinState Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, First Affiliated Hospital, Guangzhou Institute of Respiratory Health, Guangzhou Medical University, Guangzhou, China.
Nianxin FangAffiliated Dongguan People's Hospital, Dongguan Institute of Respiratory and Critical Care Medicine, Southern Medical University, Dongguan, China.
Likun ChenDepartment of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
Juhong JiangState Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, First Affiliated Hospital, Guangzhou Institute of Respiratory Health, Guangzhou Medical University, Guangzhou, China.
Haiyi DengState Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, First Affiliated Hospital, Guangzhou Institute of Respiratory Health, Guangzhou Medical University, Guangzhou, China.
Yu DengState Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, First Affiliated Hospital, Guangzhou Institute of Respiratory Health, Guangzhou Medical University, Guangzhou, China.
Minghui WanState Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, First Affiliated Hospital, Guangzhou Institute of Respiratory Health, Guangzhou Medical University, Guangzhou, China.
Guihuan QiuState Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, First Affiliated Hospital, Guangzhou Institute of Respiratory Health, Guangzhou Medical University, Guangzhou, China.
Ni SunState Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, First Affiliated Hospital, Guangzhou Institute of Respiratory Health, Guangzhou Medical University, Guangzhou, China.
Di WuShenzhen People's Hospital, The Second Clinical Medical College of Jinan University, The First Affiliated Hospital, Southern University of Science and Technology, Shenzhen, China.
Xiang LongDepartment of Respiratory Disease, Peking University Shenzhen Hospital, Shenzhen, China.
Changhao ZhongState Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, First Affiliated Hospital, Guangzhou Institute of Respiratory Health, Guangzhou Medical University, Guangzhou, China.
Xiaohong XieState Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, First Affiliated Hospital, Guangzhou Institute of Respiratory Health, Guangzhou Medical University, Guangzhou, China.
Zhanhong XieState Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, First Affiliated Hospital, Guangzhou Institute of Respiratory Health, Guangzhou Medical University, Guangzhou, China.
Ming LiuState Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, First Affiliated Hospital, Guangzhou Institute of Respiratory Health, Guangzhou Medical University, Guangzhou, China.
Ming OuyangState Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, First Affiliated Hospital, Guangzhou Institute of Respiratory Health, Guangzhou Medical University, Guangzhou, China.
Yinyin QinState Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, First Affiliated Hospital, Guangzhou Institute of Respiratory Health, Guangzhou Medical University, Guangzhou, China.
Francesco PetrellaDivision of Thoracic Surgery, European Institute of Oncology, IRCCS, Milan, Italy.
Alfonso FiorelliThoracic Surgery Unit, University of Campania Luigi Vanvitelli, Naples, Italy.
Sara BravacciniIRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
Yuki KataokaDepartment of Internal Medicine, Kyoto Min-Iren Asukai Hospital, Kyoto, Japan.
Satoshi WatanabeDepartment of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Taichiro GotoLung Cancer and Respiratory Disease Center, Yamanashi Central Hospital, Yamanashi, Japan.
Piergiorgio SolliDivision of Thoracic Surgery & Lung Transplantation, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Hitoshi IgaiDepartment of General Thoracic Surgery, Japanese Red Cross Maebashi Hospital, Maebashi, Japan.
Yuichi SaitoDepartment of Surgery, Teikyo University School of Medicine, Tokyo, Japan.
Nikolaos TsoukalasDepartment of Oncology, 401 General Military Hospital, Athens, Greece.
Takeo NakadaDivision of Thoracic Surgery, Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan.
Shiyue LiState Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, First Affiliated Hospital, Guangzhou Institute of Respiratory Health, Guangzhou Medical University, Guangzhou, China.
Rongchang ChenState Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, First Affiliated Hospital, Guangzhou Institute of Respiratory Health, Guangzhou Medical University, Guangzhou, China.
State Key Laboratory of Respiratory Disease · CNFirst Affiliated Hospital of Guangzhou Medical University · CNGuangzhou Medical University · CNJinan University · CN401 General Military Hospital of Athens · GRAzienda USL di Bologna · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITJikei University School of Medicine · JPMaebashi Red Cross Hospital · JPNiigata University · JPPeking University Shenzhen Hospital · CNSanten (Japan) · JPSouthern Medical University · CNSun Yat-sen University Cancer Center · CNTeikyo University · JPUniversity of Campania "Luigi Vanvitelli" · ITUniversity of Milan · ITYamanashi Prefectural Central Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Checkpoint inhibitor-related pneumonitis (CIP) is a lethal immune-related adverse event. However, the development process of CIP, which may provide insight into more effective management, has not been extensively examined. Methods: We conducted a multicenter retrospective analysis of 56 patients who developed CIP. Clinical characteristics, radiological features, histologic features, and laboratory tests were analyzed. After a comprehensive analysis, we proposed acute, subacute, and chronic phases of CIP and summarized each phase's characteristics. Results: There were 51 patients in the acute phase, 22 in the subacute phase, and 11 in the chronic phase. The median interval time from the beginning of CIP to the different phases was calculated (acute phase: ≤4.9 weeks; subacute phase: 4.9~13.1 weeks; and chronic phase: ≥13.1 weeks). The symptoms relieved from the acute phase to the chronic phase, and the CIP grade and Performance Status score decreased ( Conclusions: The general development process of CIP can be divided into acute, subacute, and chronic phases, upon which a better management strategy might be based devised.

Indexed as

C-Reactive ProteinImmune Checkpoint InhibitorsPneumoniaHumansImmunotherapyPrecision MedicineRetrospective StudiesC-Reactive ProteinImmune Checkpoint Inhibitorscheckpoint inhibitor-related pneumonitisclinical phasesglucocorticoidsimmune checkpoint inhibitormanagement

Identifiers

PMID35967342
PMCPMC9364904
OpenAlexW4288069474

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.